SCHEMBL285248

SCHEMBL285248

CCC(=Cc1ccc(OC)cc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
HPGD P15428 2/20 0.50
THRB P10828 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP3A4 P08684 1/20 0.50
TSHR P16473 1/20 0.50
NFKB1 P19838 1/20 0.50
APEX1 P27695 1/20 0.50
BLM P54132 1/20 0.50
PMP22 Q01453 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
ATM Q13315 1/20 0.50
TBXAS1 P24557 2/20 0.49
GSK3B P49841 2/20 0.49
AKR1C3 P42330 1/20 0.48
F3 P13726 1/20 0.47
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6659979 1.00 MAPT (0.50) MAPTALDH1A1KDM4EHPGDTHRB
SCHEMBL8419202 1.00 MAPT (0.50) MAPTALDH1A1KDM4EHPGDTHRB
Butyric Acid SCHEMBL7821663 0.91 RAB9A (0.50) MAPTALDH1A1KDM4EHPGDTHRB
Butyric Acid SCHEMBL7821661 0.91 RAB9A (0.50) MAPTALDH1A1KDM4EHPGDTHRB
SCHEMBL11652530 0.87 S100B (0.57) MAPTALDH1A1KDM4ETHRBCYP1A2
SCHEMBL5173409 0.87 TBXAS1 (0.58) ALDH1A1KDM4EHPGDCYP3A4TBXAS1
SCHEMBL489474 0.87 ALOX5 (0.48) MAPTALDH1A1KDM4EHPGDTHRB
SCHEMBL11765552 0.86 ALDH1A1 (0.49) MAPTALDH1A1KDM4EHPGDTHRB
SCHEMBL30752453 0.86 ALDH1A1 (0.49) MAPTALDH1A1KDM4EHPGDTHRB
SCHEMBL11765557 0.86 ALDH1A1 (0.49) MAPTALDH1A1KDM4EHPGDTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4687823-A1 COMPOSITION USEFUL FOR SLOWING DOWN DEGRADATION CAUSED BY LIGHT, HEAT AND/OR THE OXIDATION OF AN ACTIVE COMPOUND Sensient Cosmetic Technologies (FR) 2026-02-11 EP claimed
WO-2024208941-A1 COMPOSITION USEFUL FOR SLOWING DOWN DEGRADATION CAUSED BY LIGHT, HEAT AND/OR THE OXIDATION OF AN ACTIVE COMPOUND SENSIENT COSMETIC TECHNOLOGIES (FR) 2024-10-10 WO claimed
CN-117143811-A Human umbilical cord mesenchymal stem cell culture medium and preparation method thereof 贵州中观生物技术有限公司 2023-12-01 CN claimed
EP-2662068-B1 OIL-IN-WATER EMULSION COMPOSITION KAO CORP (JP) 2017-07-05 EP claimed
EP-0812309-B1 PROCESS FOR PREPARATION OF CINNAMATE SUNSCREEN AGENTS ISP VAN DYK INC (US) 2000-04-26 EP claimed
US-5989529-A Substantive topical composition SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. (US) 1999-11-23 US claimed
EP-4687823-A1 COMPOSITION USEFUL FOR SLOWING DOWN DEGRADATION CAUSED BY LIGHT, HEAT AND/OR THE OXIDATION OF AN ACTIVE COMPOUND Sensient Cosmetic Technologies (FR) 2026-02-11 EP disclosed
WO-2025136963-A1 CATIONIC MICRO-VESICLES AND FUNCTIONALIZED EXOSOME-LIKE VECTORS FOR THE DELIVERY OF FUNCTIONAL AGENT TO THE SKIN COTY INC. (US) 2025-06-26 WO disclosed
CN-119980263-A Sun-screening agent, sun-screening composition and preparation method of sun-screening agent 牛吉娜 2025-05-13 CN disclosed
EP-4514478-A1 SOLID COSMETIC SUNSCREEN COMPOSITION COMPRISING AT LEAST ONE CAVITY Capsum (FR) 2025-03-05 EP disclosed
WO-2024208941-A1 COMPOSITION USEFUL FOR SLOWING DOWN DEGRADATION CAUSED BY LIGHT, HEAT AND/OR THE OXIDATION OF AN ACTIVE COMPOUND SENSIENT COSMETIC TECHNOLOGIES (FR) 2024-10-10 WO disclosed
CN-117143811-A Human umbilical cord mesenchymal stem cell culture medium and preparation method thereof 贵州中观生物技术有限公司 2023-12-01 CN disclosed
WO-2023209011-A1 SOLID COSMETIC SUNSCREEN COMPOSITION COMPRISING AT LEAST ONE CAVITY CAPSUM (FR) 2023-11-02 WO disclosed
EP-1576061-A2 TITANIUM DIOXIDE COATED WITH SILICON DIOXIDE Degussa AG (DE) 2005-09-21 EP disclosed
US-20040254241-A1 Enzyme inhibitor; cognition activators KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-12-16 US disclosed
CN-1542109-A Method for extracting sun choke essential oil and sun choke brain by enzymolysis-vapor distillation process 广州大学 2004-11-03 CN disclosed
WO-2004056927-A2 TITANIUM DIOXIDE COATED WITH SILICON DIOXIDE DEGUSSA AG (DE) 2004-07-08 WO disclosed
EP-1431280-A1 ARYL SULFAMATE DERIVATIVES Kyowa Hakko Kogyo Co., Ltd (JP) 2004-06-23 EP disclosed
EP-0944613-A1 NOVEL BENZOPYRAN DERIVATIVES C & C Research Laboratories (KR) 1999-09-29 EP disclosed
WO-1998025916-A1 NOVEL BENZOPYRAN DERIVATIVES C & C RESEARCH LABORATORIES (KR) 1998-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254241-A1 Enzyme inhibitor; cognition activators SULT1A1, STS, CYP26A1 MAPT 3105/4885ALDH1A1 1187/4885KDM4E 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.